First look: tracking babies born to moms on rare disease drug
NCT ID NCT07205666
Summary
This study aims to understand the safety of the medication eplontersen during pregnancy and breastfeeding for people with a rare disease called transthyretin amyloidosis. Researchers will collect and review information from medical reports on pregnant or breastfeeding individuals who took the drug and their babies. The goal is to gather safety data on pregnancy complications and infant health outcomes to inform future use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGFrankfurt, Germany
Conditions
Explore the condition pages connected to this study.